title: Targeting N-acetylglucosamine-bearing polymer-coated liposomes to vascular smooth muscle cells.
abstract: The targeted delivery of anti-inflammatory agents has great therapeutic potential for treating restenosis following percutaneous coronary intervention. To develop a drug delivery system targeted to injured blood vessels, we examined whether N-acetylglucosamine (GlcNAc)-bearing polymer-coated liposomes (GlcNAc-Ls) are specifically taken up by vascular smooth muscle cells (VSMCs). Flow cytometric analysis revealed that GlcNAc-Ls were taken up by VSMCs in vitro. Furthermore, GlcNAc-Ls were intravenously administered to mice that had undergone wire-mediated vascular injury. GlcNAc-Ls markedly accumulated at the intramural site of the injured vessel walls but not at the contralateral (uninjured) vessel walls. These results demonstrated that GlcNAc-Ls can be specifically taken up by VSMCs both in vitro and in vivo. We propose a novel strategy of using GlcNAc-Ls that has potential for application in drug delivery targeted to injured blood vessels.
authors.affiliation: Division of Cardiovascular Sciences, Department of Organ Regeneration, Shinshu University Graduate School of Medicine, 3-1-1 Asahi, Matsumoto 390-8621, Japan.
authors.forename: Mamiko
authors.initials: M
authors.lastname: Ise
authors.forename: Hirohiko
authors.initials: H
authors.lastname: Ise
authors.forename: Yuji
authors.initials: Y
authors.lastname: Shiba
authors.forename: Satoshi
authors.initials: S
authors.lastname: Kobayashi
authors.forename: Mitsuaki
authors.initials: M
authors.lastname: Goto
authors.forename: Masafumi
authors.initials: M
authors.lastname: Takahashi
authors.forename: Toshihiro
authors.initials: T
authors.lastname: Akaike
authors.forename: Uichi
authors.initials: U
authors.lastname: Ikeda
mesh_terms: D000117:Acetylglucosamine / Q000493:pharmacokinetics*; D017130:Angioplasty; D000818:Animals; D000831:Animals, Newborn; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D002478:Cells, Cultured; D023903:Coronary Restenosis / Q000628:therapy; D016503:Drug Delivery Systems; D007275:Injections, Intravenous; D015850:Interleukin-6 / Q000378:metabolism; D008081:Liposomes / Q000493:pharmacokinetics*; D032342:Muscle Cells / Q000378:metabolism*; D009131:Muscle, Smooth, Vascular / Q000378:metabolism*; D016328:NF-kappa B / Q000493:pharmacokinetics; D051381:Rats; D017207:Rats, Sprague-Dawley; D057772:Vascular System Injuries / Q000188:drug therapy; D014746:Vimentin / Q000378:metabolism
chemical_list: D000893:Anti-Inflammatory Agents; D015850:Interleukin-6; D008081:Liposomes; D016328:NF-kappa B; D014746:Vimentin; D000117:Acetylglucosamine